NCT02463227View on ClinicalTrials.gov

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

October 31, 2016

Conditions
HIV Infections
Interventions
BIOLOGICAL

VRC01

"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."

Trial Locations (2)

19104

Penn Therapeutics, CRS, Philadelphia

35294

Alabama CRS, Birmingham

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02463227 - Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption | Biotech Hunter | Biotech Hunter